Vaccinex, Inc. has announced that it has entered into research collaboration with Schering AG to identify disease targets and potentially develop therapeutic antibodies for the treatment of certain cancers.
Vaccinex will receive a technology access fee and research funding and is eligible for milestone payments and royalties.
Following the initial research phase, Vaccinex may receive certain options to co-develop a selected cancer product with Schering AG.
Dr. Maurice Zauderer, President and CEO of Vaccinex commented, "We are very excited about applying our proprietary technologies to validate several of Schering AG's oncology targets as well as to have an opportunity to collaborate in co-developing a promising cancer product."
"We are especially pleased to be working together with an accomplished pharmaceutical partner like Schering on the discovery and development of new and innovative treatments for cancer and other diseases."